ASPECTS OF UTILIZATION AND LIMITATIONS OF ARTIFICIAL INTELLIGENCE IN DRUG SAFETY

SUJITH T; CHAKRADHAR T; SRAVANI MARPAKA; SOWMINI K

doi:10.22159/ajpcr.2021.v14i8.41979

Authors

SUJITH T Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India.
CHAKRADHAR T Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India.
SRAVANI MARPAKA Adverse drug reaction monitoring centre, Osmania Medical College, Koti, Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Hyderabad, India.
SOWMINI K Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i8.41979

Keywords:

Artificial intelligence, Machine learning, Pharmacovigilance

Abstract

Previously, it was thought that computers cannot perform the works on its own and need the human intelligence but now it is possible with the help of artificial intelligence (AI). AI has the potential to impact nearly every aspect of medical science. As pharmacovigilance (PV) deals with data concerning drug safety, it is being considered the field to be enormously transforming in near future with the emergence of AI. This article explores and gives an overall review of the researches done to implement AI technologies in PV activities. Among many of the PV activities, case processing is the most resource-consuming area, and signal detection is considered to be a poorly functioning area due to various limitations. Introducing AI will potentially fulfill the limitations in these areas and help us to use the resources in a focused way to get the real-world risk-benefit ratio for a better understanding of the safety profile of drugs and to take timely action for the well-being of people.

Downloads

Download data is not yet available.

Author Biographies

SUJITH T, Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India.

Post Graduate, Department of Pharmacology

CHAKRADHAR T, Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India.

Professor & HOD, Department of Pharmacology

SRAVANI MARPAKA, Adverse drug reaction monitoring centre, Osmania Medical College, Koti, Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Hyderabad, India.

Senior Pharmacovigilance Associate

SOWMINI K, Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India.

Post Graduate, Department of Pharmacology

References

Ventola CL. Big data and pharmacovigilance: Data mining for adverse drug events and interactions. Pharm Ther 2018;43:340-51.

El Naqa I, Murphy MJ. What is machine learning? In: El Naqa I, Li R, Murphy M, editors. Machine Learning in Radiation Oncology. Cham: Springer; 2015. p. 3-11.

Xu S. Frequentist vs Bayesian Approaches in Machine Learning. Towards Data Science; 2020. Available from: https://www.towardsdatascience.com/frequentist-vs-bayesian-approaches-in-machine-learning-86ece21e820e?source=rss----7f60cf5620c9---4. [Last accessed on 2020 Aug 27].

Kar GN, Das S. Probability and its use in Artificial Intelligence. Figshare; 2020. Available from: https://doi.org/10.6084/m9.figshare.13337768. v1. [Last accessed on 2020 Dec 06].

Bate A, Hobbiger SF. Artificial intelligence, realworld automation and the safety of medicines. Spring Nat 2020;44:125-32.

Campbell JE, Gossell-Williams M, Lee MG. A review of pharmacovigilance. West Indian Med J 2014;63:771-4.

Hauben M, Reich L. Communication of findings in pharmacovigilance: Use of the term ‘‘signal’’ and the need for precision in its use. Eur J Clin Pharmacol 2005;61:479-80.

Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: Use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther 2019;105:954-61.

Routray T, Tetarenko N, Abu-Assal C, Mockute R, Assuncao B, Chen H, et al. Application of augmented intelligence for pharmacovigilance case seriousness determination. Drug Saf 2020;43:57-66.

Tiftikci M, Ozgur A, He Y, Hur J. Machine learning-based identification and rule-based normalization of adverse drug reactions in drug labels. BMC Bioinform 2019;20 Suppl 21:707.

Dev S, Zhang S, Voyles J, Rao AS. Automated Classification of Adverse Events in Pharmacovigilance. International Conference on Bioinformatics and Biomedicine (BIBM) 2017. Kansas City, MO, USA. IEEE; 2017. p. 1562-6.

Lewis DJ, McCallum JF. Utilizing advanced technologies to augment pharmacovigilance systems: Challenges and opportunities. Ther Innov Regul Sci 2019;54:888-99.

Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol 2019;51:373-6.

Abatemarco D, Perera S, Bao SH, Desai S, Assuncao B, Tetarenko N, et al. Training augmented intelligent capabilities for pharmacovigilance: Applying deep learning approaches to individual case safety report processing. Pharm Med 2018;32:391-401.

Negi K, Pavuri A, Patel L, Jain C. A novel method for drug-adverse event extraction using machine learning. Inf Med Unlocked 2019;17:100190.

Ramesh BP, Belknap SM, Li Z, Frid N, West DP, Yu H. Automatically recognizing medication and adverse event information from food and drug administration’s adverse event reporting system narratives. JMIR Med Inform 2014;2:e10.

Hauben M, Zhou X. Quantitative methods in pharmacovigilance. Drug Saf 2003;26:159-86.

Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483-6.

Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315-21.

Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 2002;25:381-92.

Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 2012;91:1010-21.

Jahnavi Y, James K, Dsouza PL, Basavaraj BV, Subeesh V. Necessity of artificial intelligence to detect signal in the field of pharmacovigilance. J Dent Orofac Res 2020;16:71-5.

Dupuch M, Dupuch L, Perinet A, Hamon T, Grabar N. Grouping the pharmacovigilance terms with a hybrid approach. Stud Health Technol Inform 2012;180:235-9.

Henegar C, Bousquet C, Lillo-Le Louet A, Degoulet P, Jaulent MC. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance. Comput Biol Med 2006;36:748-67.

Botsis T, Scott J, Goud R, Toman P, Sutherland A, Ball R. Novel algorithms for improved pattern recognition using the US FDA adverse event network analyzer. Stud Health Technol Inform 2014;205:1178-82.

Ball R, Botsis T. Can network analysis improve pattern recognition among adverse events following immunization reported to VAERS? Clin Pharmacol Ther 2011;90:271-8.

Harpaz R, Perez H, Chase HS, Rabadan R, Hripcsak G, Friedman C. Biclustering of adverse drug events in the FDA’s spontaneous reporting system. Clin Pharmacol Ther 2011;89:243-50.

Bae JH, Baek YH, Lee JE, Song I, Lee JH, Shin JY. Machine learning for detection of safety signals from spontaneous reporting system data: Example of nivolumab and docetaxel. Front Pharmacol 2021;11:602365.

Wu Y, Wang G. Machine learning based toxicity prediction: From chemical structural description to transcriptome analysis. Int J Mol Sci 2018;19:2358.

Zhang T, Leng J, Liu Y. Deep learning for drug-drug interaction extraction from the literature: A review. Brief Bioinform 2019;21:1609-27.

Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf 2006;29:385-96.

Pappa D, Stergioulas LK. Harnessing social media data for pharmacovigilance: A review of current state of the art, challenges and future directions. Int J Data Sci Anal 2019;8:113-35.

Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. J Biomed Inf 2015;54:202-12.

Chary M, Genes N, McKenzie A, Manini AF. Leveraging social networks for toxicovigilance. J Med Toxicol 2013;9:184-91.

Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M, et al. Sorting through the safety data haystack: Using machine learning to identify individual case safety reports in social- digital media. Drug Saf 2018;41:579-90.

Nikfarjam A, Sarker A, O’Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: Mining adverse drug reaction mentions using sequence labelling with word embedding cluster features. J Am Med Inf Assoc 2015;22:671-81.

Liu J, Zhao S, Wang G. SSEL-ADE: A semi-supervised ensemble learning framework for extracting adverse drug events from social media. Artif Intell Med 2017;84:34-49.

Sampathkumar H, Chen XW, Luo B. Mining adverse drug reactions from online healthcare forums using hidden Markov model. BMC Med Inf Decis Mak 2014;14:91.

Pitts PJ, Le Louet H. Prospective pharmacovigilance. Ther Innov Regul Sci 2018;52:400-2.

Sarker A, Gonzalez G. Portable automatic text classification for adverse drug reaction detection via multi-corpus training. J Biomed Inf 2014;53:196-207.

Yang M, Kiang M, Shang W. Filtering big data from social media-building an early warning system for adverse drug reactions. J Biomed Inf 2015;54:230-40.

Mockute R, Desai S, Perera S, Assuncao B, Danysz K, Tetarenko N, et al. Artificial intelligence within pharmacovigilance: A means to identify cognitive services and the framework for their validation. Pharm Med 2019;33:109-20.

Kumar T, Sharma P, Singha M, Singh J. Big data analytics and pharmacovigilance-an ethical and legal consideration. Curr Trends Diagn Treatment 2018;2:58-65.

Keskinbora H. Medical ethics considerations on artificial intelligence. J Clin Neurosci 2019;64:277-82.